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INTRODUCTION 
 
 
             Rheumatoid arthritis (RA) is a chronic multisystem disease of 
unknown cause. Although there are a variety of systemic manifestations, 
the characteristic feature of established RA is persistent inflammatory 
synovitis, usually involving peripheral joints in a symmetric distribution. 
The potential of the synovial inflammation to cause cartilage damage and 
bone erosions and subsequent changes in joint integrity is the hallmark of 
the disease. Despite its destructive potential, the course of RA can be 
quite variable. Some patients may experience only a mild oligoarticular 
illness of brief duration with minimal joint damage, but most will have a 
relentless progressive polyarthritis with marked functional impairment.2 
       Though it is considered a disease predominantly involving the joints 
it can cause a variety of extraarticular manifestations. It can affect skin, 
eye, cardiovascular, hematological, respiratory, and nervous systems 
independent of the immunosuppressive drugs. Pulmonary involvement is 
one of the important extraarticular features of RA and occurs in the form 
of pleural diseases, pulmonary nodule, interstitial lung diseases, airway 
diseases, and pulmonary vascular disease apart from drug induced lung 
injury. 
 
REVIEW OF LITERATURE 
 
HISTORICAL REVIEW 
           Historical review revealed that Hippocrates and other Greek 
and Roman writers gave possible descriptions of the disease (Short, 
1974). There are suggestive descriptions in the Sanskrit writings of 
Charaka Samhitha of 100 AD (Sturrack et al. 1977) and by the 17th 
century English physician, Thomas Sydenham (Short, 1974).  
         Sydenham described the disease state which he called 
“Rheumatoid Polyarthritis”. But it was clearly described by Landre 
Beauvais (1800). Garrod (1959) used the term: “Rheumatoid 
Arthritis” and the clinical description of  the disease entity began to 
emerge. The modern concept of the disease evolved by the pain- 
staking work of Nicolas and Richardson (1906), Jones, Millard 
Smith (1930), Lewis Faning, Short, Bauer and Reynold (1957). 
Short’s text book (1957) set the stage for the modern era of 
investigations and inquiry in the field of Clinical Rheumatology. 
American Rheumatism Association carefully drafted the description 
and the criteria for the diagnosis of Rheumatoid Arthritis.   
           
 
 
 
 
DEFINITION 
 
        Rheumatoid Arthritis is a chronic, symmetrical, 
inflammatory, deforming polyarthritis affecting small and large 
peripheral joints with associated systemic disturbances such as 
vasculitis and nodules. Characteristically the course of the 
disease is prolonged with exacerbations and remissions.5  
GENERAL ASPECTS OF RHEUMATOID ARTHRITIS 
EPIDEMIOLOGY 
           The prevalence of RA is ~0.8% of the population (range 0.3–
2.1%) 26; women are affected approximately three times more often than 
men27. The prevalence increases with age, and sex differences diminish in 
the older age group. RA is seen throughout the world and affects all 
races. The onset is most frequent during the fourth and fifth decades of 
life, with 80% of all patients developing the disease between the ages of 
35 and 50. The incidence of RA is more than six times greater in 60- to 
64-year-old women compared to 18- to 29-year-old women. Recent data 
indicate that the incidence of RA may be diminishing. Moreover, disease 
severity appears to be declining, although it is uncertain whether this 
reflects more aggressive therapeutic interventions.2 
 AETIOLOGY 
         Rheumatoid Arthritis is a disease determined by genetic and 
environmental factors, namely an infectious agent which is systemically 
distributed in patients, but has a particular predilection for synovial joints. 
GENETIC FACTORS 
          Family studies indicate a genetic predisposition. Severe RA is 
found at approximately four times the expected rate in first-degree 
relatives of individuals with disease associated with the presence of the 
autoantibody, rheumatoid factor; 10% of patients with RA will have an 
affected first-degree relative. Moreover, monozygotic twins are at least 
four times more likely to be concordant for RA than dizygotic twins.  
           The class II major histocompatibility complex allele HLA-DR4 
and related alleles are known to be major genetic risk factors for RA. 
Early studies showed that as many as 70% of patients with RA express 
HLA-DR4 compared with 28% of control individuals (Panayi et al, 1978; 
Stastny, 1978). This association is particularly strong for individuals who 
develop RA associated with antibodies to cyclic citrullinated polypeptides 
(CCP). An association with HLA-DR4 has been noted in many 
populations, except Israeli Jews, Asian Indians, and Yakima Indians of 
North America. In these individuals, there is an association between RA 
and the closely related HLA-DR1 (Schiff et al, 1982). 
ENVIRONMENTAL FACTORS 
          Increasing urbanization and industrialization in Europe from 18th 
century onwards led to the spread of rheumatic diseases. Such a 
demographic change in the prevalence of RA seems to have been 
observed in South Africa. 
PATHOPHYSIOLOGY 
          Rheumatoid arthritis is a form of autoimmunity, the causes of 
which are still incompletely known. 
 
 
The key evidences relating to pathogenesis are: 
1. A genetic link with HLA-DR4 and related allotypes of MHC Class 
II and the T cell-associated protein PTPN22. 
2. A link with cigarette smoking that appears to be causal.  
3. A remarkable deceleration of disease progression in many cases by 
blockade of the cytokine TNF (alpha). 
4. A similar dramatic response in many cases to depletion of B 
lymphocytes, but no comparable response to depletion of T lymphocytes. 
5. A more or less random pattern of whether and when predisposed 
individuals are affected. 
6. The presence of autoantibodies to IgGFc, known as rheumatoid 
factors (RF), and antibodies to cyclic citrullinated peptides (CCP). 
                  If TNF release is stimulated by B cell products in the form of RF 
or ACPA -containing immune complexes, through activation of 
immunoglobulin Fc receptors, then RA can be seen as a form of Type III 
hypersensitivity.20 If TNF release is stimulated by T cell products such 
as interleukin-17 it might be considered closer to type IV hypersensitivity 
although this terminology may be getting somewhat dated and unhelpful.  
         It has long been suspected that certain infections could be triggers 
for this disease. The "mistaken identity" theory suggests that an infection 
triggers an immune response, leaving behind antibodies that should be 
specific to that organism. The antibodies are not sufficiently specific, 
though, and set off an immune attack against part of the host. Because the 
normal host molecule "looks like" a molecule on the offending organism 
that triggered the initial immune reaction—this phenomenon is 
called molecular mimicry. Epidemiological studies have confirmed a 
potential association between RA and two herpes 
virus infections: Epstein-Barr virus (EBV) and Human Herpes Virus 
6 (HHV-6).23 Individuals with RA are more likely to exhibit an abnormal 
immune response to the Epstein-Barr virus.24,25  
PATHOLOGY 
Disease in the joints 
           Microvascular injury and an increase in the number of synovial 
lining cells appear to be the earliest lesions in rheumatoid synovitis. 
Subsequently, perivascular infiltration with mononuclear cells is seen. 
Before the onset of clinical symptoms, the perivascular infiltrate is 
predominantly composed of myeloid cells, whereas in symptomatic 
arthritis, T cells can also be found, although their number does not appear 
to correlate with symptoms. As the process continues, the synovium 
becomes edematous and protrudes into the joint cavity as villous 
projections.2 
          Light-microscopic examination discloses a characteristic 
constellation of features, which include hyperplasia and hypertrophy of 
the synovial lining cells; focal or segmental vascular changes, including 
microvascular injury, thrombosis, and neovascularization; edema; and 
infiltration with mononuclear cells, often collected into aggregates around 
small blood vessels. Rheumatoid synovial endothelial cells express 
increased amounts of various adhesion molecules involved in the process. 
The mononuclear cell collections are variable in composition and size. 
The predominant infiltrating cell is the T lymphocyte. CD4+ T cells 
predominate over CD8+ T cells and are frequently found in close 
proximity to HLA-DR+ macrophages and dendritic cells. 
               Both polyclonal immunoglobulin and the autoantibody 
rheumatoid factor are produced within the synovial tissue, which leads to 
the local formation of immune complexes. Antibodies to synovial tissue 
components may also contribute to inflammation. Recent evidence 
suggests that antibodies to CCP, which are generated within the 
synovium, may contribute to RA synovitis. Increased numbers of 
activated mast cells are also found in the rheumatoid synovium. Local 
release of the contents of their granules may contribute to inflammation. 
Finally, the synovial fibroblasts in RA manifest evidence of activation in 
that they produce a number of enzymes such as collagenase and 
cathepsins that can degrade components of the articular matrix. These 
activated fibroblasts are particularly prominent in the lining layer and at 
the interface with bone and cartilage. Osteoclasts are also prominent at 
sites of bone erosion. 
 
Extra articular diseases 
         The most frequent tissue lesion is the subcutaneous granulomata. It 
is histologically more characteristic (moore & wilikens, 1977). These are 
found in 20% cases, usually seropositive. 
        Subcutaneous nodules have a characteristic histological appearance. 
There is a central area of fibinoid material consisting of swollen and 
fragmented collagen fibers, fibinoid exudates and cellular debris, 
surrounded by a palisade or radically arranged proliferating mononuclear 
cells. The nodules have a loose capsule of fibrous tissue.6 
         Similar granulomatous lesion may also occur in the pleura, lung, 
pericardium and sclera. Lymph nodes are often hyperplastic, showing 
many lymphoid follicles with large germinal centers and numerous 
plasma cells in the sinuses and medullary cords. Immunofluorescence 
shows that plasma cells in the synovium and lymph nodes synthesis 
rheumatoid factors.  
The 1987 revised criteria (ACR) for the classification of 
rheumatoid arthritis (RA) 1. 
1. Morning stiffness: 
         This occurs in and around the joints and lasts at least 1 hour before 
maximal improvement. 
2. Arthritis of 3 or more joint areas:   
          At least 3 joint areas simultaneously have soft-tissue swelling or 
fluid (not bony overgrowth) observed by a physician. The 14 possible 
areas include the right and left proximal interphalangeal (PIP), 
metacarpophalangeal (MCP), wrist, elbow, knee, ankle, and 
metatarsophalangeal (MTP) joints. 
3. Arthritis of hand joints:  
           At least one area in a wrist, MCP, or PIP joint is swollen. 
4. Symmetric arthritis: 
           Simultaneous involvement of the same joint areas on both sides of 
the body. Bilateral involvement of PIPs, MCPs, and MTPs is acceptable 
without absolute symmetry. 
5. Rheumatoid nodules: 
           Subcutaneous nodules are present over bony prominences or 
extensor surfaces or in juxta-articular regions. 
6. Serum Rheumatoid Factor: 
              Abnormal amounts of serum RF are demonstrated by any 
method for which the result has been positive in fewer than 5% of healthy 
control subjects. 
7. Radiographic changes: 
             Typical changes of RA on posteroanterior hand and wrist 
radiographs, which must include erosions or unequivocal bony 
decalcification localized in or most marked adjacent to the involved 
joints: Osteoarthritic changes alone do not qualify. 
                    The presence of 4 criteria supports the diagnosis of RA1. 
Criteria 1-4 must be present for at least 6 weeks, and a physician must 
observe criteria 2-5. These criteria are intended as a guideline for 
classification of patients, often for research purposes. They do not 
absolutely confirm or exclude a diagnosis of RA in a particular patient, 
especially in those with early arthritis. 
Articular manifestations of Rheumatoid Arthritis: 
          Pain, swelling, and tenderness may initially be poorly localized to 
the joints. Pain in affected joints, aggravated by movement, is the most 
common manifestation of established RA. Generalized stiffness is 
frequent and is usually greatest after periods of inactivity. Pain originates 
predominantly from the joint capsule, which is abundantly supplied with 
pain fibers and is markedly sensitive to stretching or distension. Joint 
swelling results from accumulation of synovial fluid, hypertrophy of the 
synovium, and thickening of the joint capsule.  
             Although inflammation can affect any diarthrodial joint, RA most 
often causes symmetric arthritis with characteristic involvement of certain 
specific joints such as the proximal interphalangeal and 
metacarpophalangeal joints. The distal interphalangeal joints are rarely 
involved. Synovitis of the wrist joints is a nearly uniform feature of RA 
and may lead to limitation of motion, deformity, and median nerve 
entrapment (carpal tunnel syndrome). Synovitis of the elbow joint often 
leads to flexion contractures that may develop early in the disease. The 
knee joint is commonly involved with synovial hypertrophy, chronic 
effusion, and frequently ligamentous laxity. Arthritis in the forefoot, 
ankles, and subtalar joints can produce severe pain with ambulation as 
well as a number of deformities. 
            Axial involvement is usually limited to the upper cervical spine. 
Involvement of the lumbar spine is not seen, and lower back pain cannot 
be ascribed to rheumatoid inflammation. On occasion, inflammation from 
the synovial joints and bursae of the upper cervical spine leads to 
atlantoaxial subluxation. This usually presents as pain in the occiput but 
on rare occasions may lead to compression of the spinal cord. 
             With persistent inflammation, a variety of characteristic joint 
changes develop. These can be attributed to a number of pathologic 
events, including laxity of supporting soft tissue structures; damage or 
weakening of ligaments, tendons, and the joint capsule; cartilage 
degradation; muscle imbalance; and unopposed physical forces associated 
with the use of affected joints.  
              Characteristic changes of the hand include (1) radial deviation at 
the wrist with ulnar deviation of the digits, often with palmar subluxation 
of the proximal phalanges ("Z" deformity); (2) hyperextension of the 
proximal interphalangeal joints, with compensatory flexion of the distal 
interphalangeal joints (swan-neck deformity); (3) flexion contracture of 
the proximal interphalangeal joints and extension of the distal 
interphalangeal joints (boutonnière deformity); and (4) hyperextension of 
the first interphalangeal joint and flexion of the first metacarpophalangeal 
joint with a consequent loss of thumb mobility and pinch.  
              Typical joint changes may also develop in the feet, including 
eversion at the hindfoot (subtalar joint), plantar subluxation of the 
metatarsal heads, widening of the forefoot, hallux valgus, and lateral 
deviation and dorsal subluxation of the toes. Later in the disease, 
disability is more related to structural damage to articular structures. 
Extraarticular Manifestations:   
              It is estimated that as many as 40% of patients may have 
extraarticular manifestations, and in 15% these are severe. On occasion, 
extraarticular manifestations may be the major evidence of disease 
activity and source of morbidity and require management per se. As a 
rule, these manifestations occur in individuals with high titers of 
autoantibodies to the Fc component of immunoglobulin G (rheumatoid 
factors) or with antibodies to CCP.  
          Rheumatoid nodules may develop in 20–30% of persons with RA. 
They are usually found on periarticular structures, extensor surfaces, or 
other areas subjected to mechanical pressure, but they can develop 
elsewhere, including the pleura and meninges. Common locations include 
the olecranon bursa, the proximal ulna, the Achilles tendon, and the 
occiput. They are found almost invariably in individuals with circulating 
rheumatoid factor. Histologically, rheumatoid nodules consist of a central 
zone of necrotic material including collagen fibrils, noncollagenous 
filaments, and cellular debris; a midzone of palisading macrophages that 
express HLA-DR antigens; and an outer zone of granulation tissue2.  
        Rheumatoid vasculitis, which can affect nearly any organ system, is 
seen in patients with severe RA and high titers of circulating rheumatoid 
factor. In its most aggressive form, rheumatoid vasculitis can cause 
polyneuropathy and mononeuritis multiplex, cutaneous ulceration and 
dermal necrosis, digital gangrene, and visceral infarction. 
        Rheumatoid arthritis patients are more prone to atherosclerosis, and 
risk of myocardial infarction7  and stroke is markedly increased.8 Other 
complications that may arise include: pericarditis, endocarditis, left 
ventricular failure, valvulitis and fibrosis 
         Renal amyloidosis can occur as a consequence of chronic 
inflammation.  Rheumatoid arthritis may affect the kidney glomerulus 
directly through a vasculopathy or a mesangial infiltrate but this is less 
well documented. Treatment with Penicillamine and gold salts are 
recognized causes of membranous nephropathy. 
       The eye is directly affected in the form of episcleritis which when 
severe can very rarely progress to perforating scleromalacia. Rather more 
common is the indirect effect of keratoconjunctivitis sicca, which is 
dryness of eyes and mouth caused by lymphocyte infiltration 
of lacrimal and salivary glands. When severe, dryness of the cornea can 
lead to keratitis and loss of vision. Preventive treatment of severe dryness 
with measures such as nasolacrimal duct occlusion is important. 
                 Felty's syndrome consists of chronic RA, splenomegaly, 
neutropenia, and, on occasion, anemia and thrombocytopenia. It is most 
common in individuals with long-standing disease. It may develop after 
joint inflammation has regressed. Circulating immune complexes are 
often present, and evidence of complement consumption may be seen. 
The leucopenia is a selective neutropenia with polymorphonuclear 
leukocyte counts of < 1500 cells /L.  Bone marrow examination usually 
reveals moderate hypercellularity with a paucity of mature neutrophils2. 
            RA tends to spare the central nervous system directly, although 
vasculitis can cause peripheral neuropathy. Neurologic manifestations 
may also result from atlantoaxial or midcervical spine subluxations. 
Nerve entrapment secondary to proliferative synovitis or joint deformities 
may produce neuropathies of median, ulnar, radial (interosseous branch), 
or anterior tibial nerves. 
           Anemia is by far the most common abnormality of the blood cells. 
Rheumatoid arthritis may cause a warm autoimmune hemolytic 
anemia10. The red cells are of normal size and colour (normocytic and 
normochromic). The mechanism of neutropenia is complex. An increased 
platelet count (thrombocytosis) occurs when inflammation is 
uncontrolled, as does the anemia. 
          Local osteoporosis occurs in RA around inflamed joints. It is 
postulated to be partially caused by inflammatory cytokines. More 
general osteoporosis is probably contributed to by immobility, systemic 
cytokine effects, local cytokine release in bone marrow and corticosteroid 
therapy. 
Laboratory investigations: 
Rheumatoid Factor:   
It is an auto antibody (usually of  IgM class) against the Fc portion 
of IgG and found in about 85% of patients with disease11. The presence of 
rheumatoid factor does not establish the diagnosis of RA as the predictive 
value of the presence of rheumatoid factor in determining a diagnosis of 
RA is poor. Therefore, the rheumatoid factor test is not useful as a 
screening procedure. However, the presence of rheumatoid factor can be 
of prognostic significance because patients with high titers tend to have 
more severe and progressive disease with extraarticular manifestations. 
Rheumatoid factor is uniformly found in patients with nodules or 
vasculitis. 
               Antibodies to CCP (Anti-CCP) can also be used to evaluate 
patients with RA. Although these antibodies are most commonly found in 
rheumatoid factor–positive patients, on occasion they can be detected in 
the absence of rheumatoid factor. In addition, the anti-CCP test has a 
similar sensitivity and a better specificity for RA than does rheumatoid 
factor, and, therefore, some have advocated its use to evaluate RA 
patients instead of rheumatoid factor12. This is particularly the case in 
individuals with early RA, in whom assessment of anti-CCP may be the 
most useful to confirm the diagnosis and establish a likely prognosis. The 
presence of anti-CCP is most common in persons with aggressive disease, 
with a tendency for developing bone erosions.  
                  Recently a serological point-of-care test (POCT)13 for the early 
detection of RA has been developed. This assay combines the detection 
of rheumatoid factor and anti-MCV (Anti Mutated Citrulinated Vimentin) 
for diagnosis of rheumatoid arthritis and shows a sensitivity of 72% and 
specificity of 99.7%14. 
      The erythrocyte sedimentation rate (ESR) is increased in nearly all 
patients with active RA. The levels of a variety of other acute-phase 
reactants including ceruloplasmin and C-reactive protein are also 
elevated, and generally such elevations correlate with disease activity. 
          Synovial fluid analysis confirms the presence of inflammatory 
arthritis, although none of the findings is specific. The fluid is usually 
turbid, with reduced viscosity, increased protein content, and a slightly 
decreased or normal glucose concentration.  
A synovial fluid white blood cell count >2000/ L with >75% 
polymorphonuclear leukocytes is highly characteristic of inflammatory 
arthritis, although not diagnostic of RA.  
 
Radiological findings: 
             In Rheumatoid arthritis, there may be no changes in the early 
stages of the disease, or the x-ray may demonstrate juxta-articular 
osteopenia, soft tissue swelling and loss of joint space. As the disease 
advances, there may be bony erosions and subluxation.  
          Magnetic resonance imaging and ultrasound are also used in 
rheumatoid arthritis. There have been technical advances in 
ultrasonography. High-frequency transducers (10 MHz or higher) have 
improved the spatial resolution of Ultrasound images; these images can 
depict 20% more erosions than conventional radiography. Also, color 
Doppler and power Doppler ultrasound, which show vascular signals of 
active synovitis, are useful in assessing synovial inflammation. This is 
important, since in the early stages of rheumatoid arthritis, the synovium 
is primarily affected, and synovitis seems to be the best predictive marker 
of future joint damage.15 
 
Management of Rheumatoid Arthritis: 
              The goals of therapy of RA include relief of pain, reduction of 
inflammation, protection of articular structures, maintenance of function, 
and control of systemic involvement2. Management of patients with RA 
involves an interdisciplinary approach, which attempts to deal with the 
various problems that these individuals encounter with functional as well 
as psychosocial interactions.  
DRUG THERAPY18:   Five groups of drugs are commonly used. 
i. Use of Nonsteroidal anti-inflammatory drugs (NSAIDs) and simple 
analgesics to control the symptoms and signs of the local inflammatory 
process. These agents are rapidly effective at mitigating signs and 
symptoms, but they appear to exert minimal effect on the progression of 
the disease. 
ii. Low-dose oral Glucocorticoids: An initial course of low-dose 
glucocorticoids should be considered in patients either alone or with 
disease modifying anti-rheumatic drugs (DMARDs)19. Intraarticular 
glucocorticoids can often provide transient symptomatic relief when 
systemic medical therapy has failed to resolve inflammation. 
iii. DMARDs: These agents appear to have the capacity to decrease elevated 
levels of acute-phase reactants in treated patients and, therefore, are 
thought to modify the inflammatory component of RA and thus its 
destructive capacity. These agents include methotrexate, sulfasalazine, 
hydroxychloroquine, gold salts, or D-penicillamine.  
iv. Biologics16: which include TNG-neutralizing agents (infliximab, 
etanercept, and adalimumab), IL-1-neutralizing agents (anakinra), those 
that deplete B cells (rituximab)17, and those that interfere with T cell 
activation (abatacept). These agents have been shown to have a major 
impact on the signs and symptoms of RA and also to slow progressive 
damage to articular structures. 
v. Immunosuppressive and cytotoxic drugs: include leflunomide, 
cyclosporine, azathioprine, and cyclophosphamide. 
                Substituting omega-3 fatty acids such as eicosapentaenoic acid 
found in certain fish oils for dietary omega-6 essential fatty acids found in 
meat has also been shown to provide symptomatic improvement in 
patients with RA2.  
PULMONARY MANIFESTATIONS IN RHEUMATOID 
ARTHRITIS: 
           Pulmonary manifestations of RA were first described in 1948, 
when Ellman and Ball recognized diffuse pulmonary fibrosis in three 
patients with RA.31 Pulmonary disease, which is a major source of 
morbidity and mortality in RA, manifests most commonly as interstitial 
lung disease (ILD), airways disease, rheumatoid nodules, and pleural 
effusions. Respiratory manifestations usually become more prevalent as 
RA progresses, but they may present simultaneously with joint symptoms 
or even predate joint involvement.28 Many pulmonary manifestations are 
directly linked to RA itself and may be a result of underlying defects in 
immunity and chronic inflammation.29Some are due to exposures and to 
the treatment of RA with disease-modifying antirheumatic drugs 
(DMARDs).30 In unselected populations, up to a third of subjects describe 
important respiratory symptoms35, but two-thirds or more may have 
significant radiographic abnormalities on high-resolution computed 
tomography (HRCT). 
PARENCHYMAL LUNG DISEASE 
PULMONARY NODULES: 
         Rheumatoid nodules (necrobiotic nodules) are found in up to 20% 
of patients .21   Nodules typically range from a millimeter to centimeters in 
size, and are usually asymptomatic. However, complications include 
pneumothorax, hydropneumothorax, sterile empyema, and hemoptysis. 
Nodules identified on HRCT must be distinguished from malignant and 
infectious lesions.  
Caplan's syndrome refers to conglomerations of nodules seen in 
patients with the combination of RA and pneumoconiosis.22 
 
INTERSTITIAL LUNG DISEASE 
      The prevalence of interstitial lung disease (ILD) varies depending on 
the criteria used to establish the diagnosis. In retrospective studies, 
clinically significant ILD has been described in approximately 7% of 
subjects 33, whereas autopsy studies have described a prevalence of up to 
35% 34. Prospective studies that use HRCT, the most sensitive technique 
for the detection of RA-related lung disease35, to specifically screen for 
disease have shown a much higher prevalence. In unselected populations, 
specific features of ILD will be seen in up to two-thirds of individuals 36. 
         Unlike most other connective tissue diseases, the usual 
interstitial pneumonia (UIP) pattern is more commonly seen on surgical 
lung biopsy than nonspecific interstitial pneumonia (NSIP). 
Lymphocytic interstitial pneumonia (LIP) and organizing pneumonia 
(OP) have also been described37. Acute interstitial pneumonia ( Haman-
Rich syndrome), on the other hand, is quite uncommon, but presents with 
a rapid and aggressive course that frequently results in death. 
PREDICTORS OF THE DEVELOPMENT OF RA-ILD 
 
                 Clinical, genetic, and environmental factors have been used to 
predict the development of lung disease in RA. Risk factors for the 
development of RA-ILD include older age, male sex, and a history of 
cigarette smoking. Sex influences both the risk as well as the pattern of 
organ involvement. Both rheumatoid nodules and RA-ILD are more 
commonly seen in men .38 Active or previous tobacco smoking is an 
independent risk factor for the development of RA39, its severity, and its 
rheumatoid factor (RF) seropositivity40. A mechanistic connection has 
also been proposed for a relationship between tobacco smoke, the HLA-
DRB1 "shared epitope" (SE), anticyclic citrullinated peptide antibody 
(anti-CCP), and the development of RA41. The combination of a history 
of tobacco smoking and the presence of two copies of the HLA-DR SE 
genes increased the risk for RA 21-fold compared with the risk among 
nonsmokers carrying no SE genes. Smoking has been 
independently associated with the development of radiographic and 
physiologic abnormalities consistent with ILD. 
        Patients with anti-CCP antibodies or IgA and/or IgM RF 
autoantibodies represent a group at highest risk for the development of 
clinically significant articular and extraarticular RA 42. High-titer RF has 
been associated with the presence of RA-ILD and a decreased DLCO.43 
The role of anti-CCP antibodies in the lung is unknown. 
Pathology 
           A cellular inflammatory process is required for and initiates a 
secondary fibroproliferative process, which may become progressive and 
independent of its initiating cause. In patients  with hypersensitivity 
pneumonitis , reversible  granulomatous inflammation is generally seen. 
However, once the fibroproliferative process begins, the clinical course 
and gene expression profile become similar to those of IPF, 
the prototypical fibrosing lung disease, and the disease 
becomes unresponsive to immunosuppression.44,45  
          Histologically in early stages an interstitial infiltrate predominates, 
composed of lymphocytes, plasma cells and histiocytes.9 With 
progression the infiltrate is replaced by fibrous tissue. 
Immunofluroscence studies demonstrate Ig, largely IgM in alveolar and 
arterial walls. Immune complex deposition in the lung interstitium and 
alveolar walls contributes to alveolar macrophage activation. It may play 
a role in enhancing the pathogenicity of immune complex mediated injury 
in the lungs as ILD in rheumatoid arthritis is commonly seen in patients 
with high titers of rheumatoid factor. 
            The presence of areas of lymphoplasmacytic infiltrate is associated 
with physiologic improvement in response to cyclophosphamide and 
corticosteroid therapy, whereas fibroblast foci and areas of airspace 
organization were associated with a decline in function46. 
 
 
 
CURRENT THERAPIES FOR RA-ILD 
         The effective treatment of the joint disease should not be used as a 
surrogate for beneficial or even adequate treatment of the ILD.  
Tumor necrosis factor-alpha antagonist  therapy has been hinted to slow 
the progression of RA-related pulmonary fibrosis47, it has also been 
associated with the development of fulminate respiratory failure48. In 
several case reports, corticosteroids have been suggested as a treatment of 
the ILD characterized by organizing pneumonia pathologic pattern 49. 
Cyclosporine has been used to treat both acute pneumonitis and 
progressive pulmonary fibrosis with success in individual patients .50 The 
use of rituximab and abatacept for the treatment of refractory RA 
synovitis is supported by current data, but their use in the treatment of the 
pulmonary manifestations of RA remains unclear 51. 
            Mycophenolate moefetil has recently been reported in small case 
series to have a beneficial effect on CTD-ILD, and may be considered in 
this setting.53 Rapidly progressive or extensive disease with arterial 
hypoxemia is often treated with either daily oral or monthly intravenous 
cyclophosphamide in combination with corticosteroids.52 Patients with 
severe, fibrotic lung disease should be considered for referral for lung 
transplantation. Given the clinical impact of RA-ILD, and the absence of 
definitive data on its treatment, prospective, controlled studies are 
necessary to guide the field. 
 
PLEURAL DISEASES 
 
         Pleurisy, pleuritis, and effusions occur in approximately 5% of 
patients 54 The most common pulmonary manifestation of RA is pleural 
effusion.  Effusions tend to be small, asymmetric, and to wax and wane.  
Pleural fluid analysis generally reveals a low glucose (< 50 mg/dl), low 
pH (< 7.30), high lactate dehydrogenase (LDH) (> 1,000), and high 
rheumatoid factor titers.55  Effusions in patients with RA cannot be 
assumed to be RA associated; infections, empyema, sterile empyema, 
chylothorax, and congestive heart failure (CHF) are all seen. 
            Asymptomatic pleural effusions need not be treated. For patients 
with RA who have symptomatic pleural effusions, various studies have 
reported that repeated thoracentesis, pleurodesis (using either talc, 
bleomycin, or tetracycline), and administration of corticosteroids can be 
beneficial56. 
 
 
 
AIRWAY DISEASES: (CRICOARYTENOID ARTHRITIS, 
BRONCHIECTASIS, BRONCHIOLITIS) 
            RA can cause upper, lower, and small, distal airway disease .57 
Cricoarytenoid arthritis may present with hoarseness, pain, change in 
voice, or globus. Upper airway complications, such as rheumatoid 
nodules and vocal cord paresis, also occur. There is a high incidence of 
radiographic bronchiectasis, up to 30% in some HRCT studies58; 
however, clinically significant disease is much less frequent. Symptoms 
are identical to other causes of bronchiectasis and include cough, 
sputum production, frequent episodes of infection, and hemoptysis. Small 
airway disease with physiologic obstruction is common 59, and presents 
with exertional dyspnea, a nonproductive cough, or wheezing. HRCT is 
suggestive of small airway disease when it demonstrates centrilobular 
nodules, hyperinflation, and heterogenous air trapping. Pathologically, 
both fibrosing (obliterative or constrictive bronchiolitis) and cellular 
(diffuse pan bronchiolitis and follicular bronchiolitis) have been 
well described.60 
BRONCHIECTASIS: 
          The prevalence of bronchiectasis in RA ranges from 30% to 58% 
when detected by HRCT.68 HRCT is more sensitive than respiratory 
symptoms, PFTs, or chest radiograph for the presence of bronchiectasis. 
Both cylindrical and traction bronchiectasis occur and may accompany 
RA-ILD. Clinically evident bronchiectasis is much less frequent (1%–5% 
of RA patients) and may precede the onset of the articular symptoms and 
the diagnosis of RA.69 The high prevalence of bronchiectasis in RA may 
be the result of defects in humoral immunity, with increased 
susceptibility to respiratory infections, and subsequent structural damage 
to the airways.70Genetic predisposition may also play a role. Overall 
survival may be decreased in RA patients with bronchiectasis, 
predominantly due to infections and acute respiratory failure.  
Bronchiectasis tends to develop late in RA, particularly in women with 
RF seropositive and nodular disease. 
BRONCHIOLITIS OBLITERANS (BO): 
        Bronchiolitis obliterans (BO) is disorder of the small airways, 
pathologically characterized by obliterative bronchiolitis with 
circumferential narrowing, ulceration, and scarring of the terminal and 
respiratory bronchioles. BO is characterized clinically by progressive 
dyspnea accompanied by dry cough.61 hyperinflation and air trapping 
may be present, although in later stages of disease, both restrictive and 
obstructive physiology due to the severity of the air trapping may be 
observed. HRCT may be more sensitive than PFTs for detecting small 
airways disease. The radiographic appearance is that of moderate to 
severe air trapping, as demonstrated by a mosaic pattern of patchy or 
segmental regions of decreased lung attenuation that are accentuated on 
expiratory images BO generally has a poor prognosis, with inexorable 
progression and poor response to corticosteroids61. 
PULMONARY VASCULAR DISEASE: 
          Rheumatoid pulmonary vascular involvement produces pulmonary 
vasculitis, primary and secondary pulmonary hypertension. Secondary 
pulmonary hypertension may result due to advanced interstitial lung 
disease. 
          Diffuse alveolar hemorrhage (DAH) due to pulmonary capillaritis 
has been described in association with RA but is extremely rare.62 HRCT 
features include diffuse ground-glass opacities and alveolar opacities, 
which are relatively nonspecific findings and can appear similar to 
pulmonary edema, diffuse infection, or a drug reaction. The diagnosis of 
DAH is confirmed in the correct clinical setting by bronchoscopy with 
BAL, in which progressively bloodier fluid is obtained on serial lavage 
specimens. 
DRUG INDUCED LUNG INJURY: 
          The mechanism of methotrexate-related pulmonary toxicity is 
unknown. However, it is thought to be an idiosyncratic or 
hypersensitivity reaction rather than being related to cumulative dose63. 
Although it is not possible to predict which patients will develop 
pulmonary toxicity, patients with underlying rheumatoid pleural or 
pulmonary disease may be at increased risk. Clinical presentations vary 
and may include the indolent onset of pulmonary fibrosis, acute lung 
injury with diffuse alveolar damage (DAD), rapidly progressive 
pulmonary fibrosis, pleuritis, pleural effusions, nodulosis, or bronchitis 
with airways hyperreactivity and cough64,65 Distinguishing methotrexate 
toxicity from infection and RA-ILD is difficult. On surgical lung biopsy, 
several different pathologic patterns may be consistent with drug toxicity, 
including cellular interstitial infiltrates, granulomas, infiltration with 
eosinophils, and a diffuse alveolar damage pattern with concomitant 
perivascular inflammation66. Therapy is mainly supportive, usually 
starting with withdrawal of methotrexate therapy alone, although often 
empirical antibiotic therapy is also administered. In severe cases, 
corticosteroids may be used; for some patients, other immunosuppressive 
therapy, such as azathioprine or cyclophosphamide, may be required. 
                Gold-induced pneumonitis manifests typically with rapid onset 
of cough, fever, and dyspnea, usually within the first 6 months of therapy. 
D-Penicillamine has been associated with ILD, BO, and a pulmonary-
renal syndrome with alveolar Hemorrhage67. Toxicity has been associated 
with peripheral blood eosinophilia and elevated serum IgE levels.  
PULMONARY FUNCTION TESTS: 
                   Pulmonary function testing is a valuable tool for evaluating 
the respiratory system, representing an important adjunct to the patient 
history, various lung imaging studies, and invasive testing such as 
bronchoscopy and open-lung biopsy. Insight into underlying 
pathophysiology can often be gained by comparing the measured values 
for pulmonary function tests obtained on a patient at any particular point 
with normative values derived from population studies. The percentage of 
predicted normal is used to grade the severity of the abnormality. 
Pulmonary function tests (PFTs) is a generic term used to indicate a 
battery of studies or maneuvers that may be performed using standardized 
equipment to measure lung function. PFTs can include simple screening 
spirometry, formal lung volume measurement, diffusing capacity for 
carbon monoxide, and arterial blood gases.  Pulmonary function studies 
measure and record the properties of four lung components. These 
include the airways (large and small), lung parenchyma (alveoli, 
interstitium), pulmonary vasculature, and the bellows-pump mechanisms. 
Spirometry: 
           Spirometry is the most commonly used lung function screening 
study.   A spirogram is a graphic representation of bulk air movement 
depicted as a volume-time tracing or as a flow-volume tracing. Values 
generated from a simple spirogram provide important graphic and 
numeric data regarding the mechanical properties of the lungs, including 
airflow (forced expiratory volume in 1 second [FEV1]) and exhaled lung 
volume (FVC). The most common parameters measured in Spirometry 
are Vital capacity (VC), Forced vital capacity (FVC), Forced expiratory 
volume (FEV) at timed intervals of 0.5, 1.0 (FEV1), 2.0, and 3.0 seconds, 
Forced expiratory flow 25–75% (FEF 25–75) and Maximal voluntary 
ventilation (MVV). 
            Results are usually given in both raw data (litres, litres per 
second) and percent predicted - the test result as a percent of the 
"predicted values" for the patients of similar characteristics (height, age, 
sex, race and weight). The interpretation of the results can vary 
depending on the physician and the source of the predicted values. 
Generally speaking, results nearest to 100% predicted are the most 
normal and results over 80% are often considered normal71.  
Data from a spirogram provide important clues to help distinguish 
obstructive pulmonary disorders that typically reduce airflow, such as 
asthma and emphysema, from restrictive disorders that typically reduce 
total lung volumes, including pulmonary fibrosis and neuromuscular 
disease. 
 
Forced Expiratory Volume in one Second (FEV1): 
 
            The FEV1 is the most widely used parameter to measure the 
mechanical properties of the lungs. In normal persons, the FEV1 accounts 
for the greatest part of the exhaled volume from a spirometric maneuver 
and reflect mechanical properties of the large and the medium-sized 
airways. In a normal flow-volume loop, the FEV1 occurs at about 75% to 
85% of the FVC. This parameter is reduced in obstructive and restrictive 
disorders.  
Forced Vital Capacity 
              FVC is a measure of lung volume and is usually reduced in 
diseases that cause the lungs to be smaller. Such processes are generally 
termed restrictive and can include disorders of the lung parenchyma, such 
as pulmonary fibrosis, or of the bellows, including kyphoscoliosis, 
neuromuscular disease, and pleural effusion. However, a reduction in 
FVC is not always due to reduced total volumes and can occur in the 
setting of large lungs hyperinflated due to severe airflow obstruction and 
air trapping, as in emphysema. This phenomenon referred to as pseudo 
restriction. Reduced FVC can occur despite a normal or increased total 
lung volume. Therefore, FVC is not a reliable indicator of total lung 
capacity or restriction, especially in the setting of airflow obstruction. The 
overall accuracy of the FVC for restriction is about 60%.74 
FEV1/FVC ratio (FEV1%) 
 
           In healthy adults this should be approximately 75–80%. In 
obstructive diseases (asthma, COPD, chronic bronchitis, emphysema) 
FEV1 is diminished because of increased airway resistance to expiratory 
flow and the FVC may be decreased (for instance by premature closure of 
airway in expiration). This generates a reduced value (<80%, often 
~45%). In restrictive diseases (such as pulmonary fibrosis) the FEV1 and 
FVC are both reduced proportionally and the value may be normal or 
even increased as a result of decreased lung compliance. 
Forced Expiratory Flow (FEF) 
             Forced Expiratory Flow (FEF) is the flow (or speed) of air 
coming out of the lung during the middle portion of a forced expiration. It 
can be given at discrete times, generally defined by what fraction remains 
of the functional vital capacity (FVC). The usual intervals are 25%, 50% 
and 75% (FEF25, FEF50 and FEF75), or 25% and 50% of FVC. It can 
also be given as a mean of the flow during an interval, also generally 
delimited by when specific fractions remain of FVC, usually 25–75% 
(FEF25–75%).72 FEF 25–75% or 25–50% gives an indication of what is 
happening in the lower airways. It is a more sensitive parameter and not 
as reproducible as the others. It is a useful serial measurement because it 
will be affected before FEV1, so can act as an early warning sign of small 
airway disease. 
          MMEF or MEF stands for maximal (mid) expiratory flow and is 
the peak of expiratory flow as taken from the flow-volume curve and 
measured in liters per second. It should theoretically be identical to peak 
expiratory flow (PEF), which is, however, generally measured by a peak 
flow meter and given in liters per minute.73 
MEASUREMENT OBSTRUCTIVE 
PATTERN
RESTRICTIVE 
PATTERN 
FVC Reduced or normal reduced 
FEV1 reduced normal or reduced 
FEV1/FVC reduced normal or increased 
TLC normal or increased reduced 
 
Diffusing Capacity 
 
             Spirometry and lung volumes elucidate the mechanics of 
ventilation but do not address the gas-transfer function of the lung. With 
use of a highly diffusable gas (carbon monoxide [CO]) as a surrogate for 
oxygen, the diffusing capacity of lung for CO (DLCO) estimates the 
patient’s ability to absorb alveolar gases. Diffusion in the lungs is most 
efficient when the surface area for gas transfer is high and the blood is 
readily able to accept the gas being transferred. It is thus decreased in: 
• Conditions that minimize the ability of the blood to accept and bind the 
gas that is diffusing (eg, anemia) 
• Conditions that decrease the surface area of the alveolar-capillary 
membrane (eg, emphysema, pulmonary embolism) 
• To a smaller degree, conditions that alter the membrane’s permeability 
or increase its thickness (eg, pulmonary fibrosis). 
Conversely, conditions resulting in an increased effective pulmonary 
blood volume cause an elevated DLCO75. 
            The gas used to test the diffusing capacity must be more soluble in 
blood than in lung tissue. Ideally, the amount of gas entering the blood 
should be limited by the lungs’ ability to transfer it and not by lung 
perfusion (i.e., the gas must avidly bind to hemoglobin). Carbon 
monoxide is the gas used, as it most closely meets these requirements.76 
          In RA-ILD, PFTs typically show restrictive physiology and 
diffusion impairment. A defect in DLCO is often the earliest PFT finding 
in RA-ILD.77 Exercise testing is rarely used for screening; however, it is 
important to ambulate patients with RA-ILD because resting oximetry 
may be falsely reassuring. Oxygen desaturation on 6-minute walk testing 
is predicted by abnormalities in lung function.78 
             There are 2 major mechanisms for exertional hypoxemia in ILD. 
First, an inappropriate decrease in DLCO during exercise due to 
inadequate pulmonary capillary recruitment leads to a relatively smaller 
capillary blood volume and subsequently reduced time available for gas 
exchange.79 Second, patients with ILD have a reduced mixed venous 
oxygen content due to areas of ventilation/ perfusion mismatch and 
intrapulmonary shunt.79 Late in disease, fibrosis and pulmonary vascular 
obliteration lead to severe diffusion abnormalities, with resting arterial 
hypoxemia  and profound exertional desaturation. 
Chest Radiography: 
       Evidence of interstitial fibrosis is seen at chest radiography in 
approximately 5% of patients with rheumatoid arthritis . The chest 
radiograph may be normal in patients with early fibrosis. In late stages, 
chest radiograph shows changes identical to that of Interstitial Pulmonary 
Fibrosis (IPF).  Chest radiographs typically show a fine reticular or 
reticulonodular pattern involving the lower lung zones in early stages. 
With progression of disease, the reticular pattern becomes more coarse 
and diffuse, and honeycombing may be seen .It is useful in detecting 
clinically significant pleural effusion and rheumatoid nodules. 
High resolution computed tomography: 
         The use of cross sectional images in CT makes it possible to 
distinguish between densities and provide accurate size assessment of 
lesions. With high resolution CT, the thickness of individual cross 
sectional images is approximately 1 to 2 mm rather than the usual 10 mm 
and the images are reconstructed with high spatial resolution algorithms.  
                 HRCT is the gold standard for diagnosis of ILD80. On HRCT, 
the appearance of RA with interstitial fibrosis is usually indistinguishable 
from that of IPF and includes traction bronchiectasis, intralobular septal 
thickening, irregular interlobular septal thickening, irregular interfaces, 
honeycombing, Ground Glass Opacities (GGO), peripheral and 
subpleural predominance of fibrosis or GGO, lower lung zone and 
posterior predominance, pleural thickening and effusion. Honeycombing 
is seen less commonly than in IPF; however predominant GGO is seen 
more commonly in patients with RA. Evidence of GGO as a predominant 
finding in the absence of honeycombing is associated with active 
alveolitis. This is usually considered a feature of early and potentially 
reversible disease. Radiographically abnormalities are indistinguishable 
from ILD caused by other diseases. Progression to end-stage fibrosis 
results in the classical honeycombing pattern. Coexisting pleural effusion 
is common. HRCT is much more sensitive than plain chest radiography in 
the assessment of ILD and its higher sensitivity should allow an earlier 
diagnosis81. The coexistence of airway thickening and dilatation outside 
the fibrotic area is also highly suggestive of RA. HRCT shows similar 
lesions, including GGO, basal honeycombing, traction bronchiectasis and 
emphysema.82 Other changes of RA on HRCT include BOOP, 
bronchiectasis and bronchial disease, consolidation, enlarged lymph 
nodes and nodules that are predominantly subpleural in location. 
Bronchiectasis is seen in up to a third of patients. 
             In RA, it is common to see several histopathologic and/or 
radiographic patterns simultaneously, for example, the presence of 
airways disease or rheumatoid nodules in conjunction with ILD. When 
observed serially, HRCT manifestations in RA-ILD may include either 
acute exacerbations of disease, characterized by the onset of diffuse 
ground-glass opacities, or progressive fibrosis, characterized by 
increasing reticularity and honeycombing.83 
BRONCHO ALVEOLAR LAVAGE: 
         The Bronchoscope can be used to sample material from the distal 
pulmonary parenchyma. The upper airway is anaesthetized and the 
bronchoscope is introduced and wedged into a subsegmental airway. 
Aliquots of sterile saline are introduced through the scope. This allows 
sampling of the cells and organisms from the alveolar spaces. The lavage 
is filtered and the cells are stained with Papanicolaou’s method and 
differential count is performed. 
         The role of bronchoalveolar lavage (BAL) in connective tissue 
disease-associated ILD (CTD-ILD) is discussed in detail in the article by 
Kowal-Bielecka and colleagues elsewhere in this issue. In RA-ILD, BAL 
has not proven useful for diagnosis.84   Nonetheless, BAL is important in 
the evaluation of radiographic abnormalities, primarily in the evaluation 
of alternative diagnoses to RA-ILD, including drug reaction, diffuse 
alveolar hemorrhage, and opportunistic infection.85 Bronchoscopy with 
BAL should be considered in the evaluation of new infiltrates in any RA 
patient receiving immunosuppressive therapy. 
LUNG BIOPSY: 
            Surgical lung biopsy is not commonly obtained in RA patients. 
However, specific pathologic patterns may help determine prognosis and 
response to treatment. The pathologic patterns observed in RA-ILD are 
similar to those in the idiopathic interstitial pneumonias. However, 
certain findings, such as lymphoid hyperplasia and plasma cell 
infiltration, are more common in RA-ILD.86 One notable feature of RA-
ILD is that more than one pathologic process, and often several, may 
occur in the same biopsy specimen, making comparison among series 
particularly difficult.87 
                UIP and NSIP are the most common histopathologic patterns in 
RA .UIP is more common than NSIP. UIP is characterized by a 
heterogeneous pattern in which areas of normal lung are interspersed with 
areas of active fibrosis (known as fibroblastic foci), interstitial 
inflammation, and honeycombing. The changes are usually most 
pronounced in the subpleural lung.  
          The features of NSIP, by contrast, are diffuse and spatially 
homogeneous88. There are 2 forms of NSIP: 1) cellular NSIP, which is 
characterized by lymphocytic and plasma cell infiltrates with minimal 
fibrosis; and 2) fibrotic NSIP, which is characterized by fibrotic changes, 
either alone or in combination with patchy areas of inflammation. 
             Organising Pneumonia is the primary pattern on biopsy in 10% to 
22% of cases and is a secondary component in a significant number of 
RA-ILD cases.86 This pattern may be primarily due to RA but can be 
caused by drug hypersensitivity, having been reported in association with 
methotrexate, etanercept, rituximab, and sulfasalazine.65 
 
 
 
 
 
 
 
 
 
 
  
 
 
                            AIMS AND OBJECTIVES 
 
1. To study the pulmonary manifestations of 
Rheumatoid arthritis. 
2. To correlate the HRCT findings with pulmonary 
function test. 
 
 
 
 
 
                        MATERIALS AND METHODS 
 
Setting                      : Department of Medicine. Govt. Rajaji Hospital 
Design                      : Cross Sectional Study. 
Period of study         : One year. 
Ethical approval       : Obtained from ethical committee, headed   
                                    By Dean, Govt. Rajaji Hospital. 
Consent                    : Obtained from all patients. 
Statistical software   : EPI Info 2008. 
Study population      : Patients attending Rheumatology OP with  
         Rheumatoid  Arthritis. 
Inclusion criteria: 
1)   Patients who satisfied Revised American Rheumatologic Association  
criteria 1987, who have either respiratory symptoms or signs, irrespective 
of age, sex and duration of disease. 
Exclusion criteria: 
1) Previous history of Bronchial asthma/ Chronic Obstructive Airway 
Disease. 
2) Patients with respiratory infections, including pulmonary tuberculosis. 
3) Previous history of pulmonary tuberculosis. 
4) Patients who are smokers. 
5) Patients with occupation prone to develop occupational lung disease. 
6) Those who have mixed disorder like SLE and RA; SS and RA; and 
MCTD and overlap syndrome. 
           Forty five patients attending Rheumatology clinic, Govt. Rajaji 
Hospital, Madurai, who were diagnosed to have Rheumatoid Arthritis, 
and having respiratory symptoms or signs were selected for the study. 
        The selected patients were evaluated with detailed history regarding 
the duration of disease, history of drug intake, type of onset of symptoms 
were noted. 
         Presence of joint swelling, tenderness and number of tender joints, 
number of swollen joints were noted. Detailed clinical examination was 
done especially for rheumatoid nodule and joint deformities. All systems 
were examined carefully and visual analogue pain score was carefully 
assessed. A detailed respiratory system examination was done with 
special attention to presence of pleural effusion, crepitations and wheeze. 
        Hemoglobin, White blood cell count, Differential count, Blood Urea, 
Serum Creatinine, Blood sugar, ESR, LFT, Rheumatoid Factor and C 
Reactive Protein by latex agglutination test and Chest X ray were done 
for all patients. 
      Disease Activity Score was calculated for every patients. 
DAS 28 score  
      Disease activity score is a composite score using tender and swollen 
joint count, ESR and patient’s global assessment activity using a 10 mm 
visual analogue scale.  
         DAS28= 0.56 √(tender joints) + 0.28√(swollen joints) 
                         + 0.70 Log (ESR) + 0.014(VAS in mm) 
Classification  
 
          Mild ≤ 3.1 
Moderate 3.2- 5.1 
Severe > 5.1     
(Minimum score= 0; Maximum score= 9) 
             After assessing baseline clinical and laboratory parameters, all 
patients were subjected to spirometric evaluation and High Resolution 
Computerized Tomography (HRCT). 
          The Spirometry was performed using Knudsen’s computerized 
Spirometer.  All the Spirometric parameters were expressed as percentage 
of predicted value for that particular age, sex, height, and weight 
comparable to South Indian population defined by Knudsen et al. 
         The entire test was repeated on three occasions and the best of the 
three readings were taken. Among the various spirometric parameters, the 
following were analyzed. 
 
1. Forced Vital Capacity (FVC). 
2. Forced Expiratory Volume in first second (FEV1). 
3. Percentage of FVC expelled as FEV1 (FEV1/FVC) 
        All the patients were subjected to HRCT after getting informed 
consent. 
Serial slices 2 mm in width and 10 mm apart were taken from the 
apex of the lung to base and reconstructed on a High-resolution bone 
algorithm. HRCT was done from the Department of Radiology, Govt. 
Rajaji Hospital, Madurai. Reports were given by qualified Radiologists.  
        The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008). Using 
the software range, frequencies, percentage, mean, standard deviation and 
p value were calculated.   P value of < 0.05 was taken as significant. 
 
 
 
 
 
 
 
            RESULTS AND ANALYSIS OF OBSERVED 
DATA  
 
 
TABLE 1. SEX DISTRIBUTION AMONG PATIENTS: 
 
 
 
 
 
 
 
In this study out of 45 cases, 35 are females and 10 are males. 
The females are 78% and males are 22%. Sex ratio= 3.5:1 ( F:M). 
 
TABLE 2: AGE DISTRIBUTION AMONG STUDY POPULATION:  
 
The age of patients ranges between 32 to 65 years. Mean age was 
47.7 years. Most number of cases was from age group of 50-59 years. 
 
Sex No. of patients % 
Male 10 22.2 
Female 35 77.7 
Age group FEMALE MALE No. of 
patients
Percentage 
30- 39 years 9 1 10 22.2% 
40- 49 years 10 4 14 31.1% 
50- 59 years 12 4 16 35.6% 
>60 years 4 1 5 11.1% 
TOTAL 35 10 45 100% 
 
 
 
TABLE 3: PATTERN OF SYMPTOMS AMONG PATIENTS: 
 
SYMPTOMS NO. OF 
PATIENTS 
PERCENTAGE 
Dry cough 9 20% 
Cough with expectoration 3 6.66% 
Exertional dyspnoea 21 46.66% 
Chest pain 6 13.33% 
Dry cough with dyspnoea 9 20% 
No symptoms 5 11.11% 
 
Most of the patient had dyspnoea on exertion (47%) as their respiratory 
symptom. Twenty percent of patients had dry cough.   
TABLE 4: DURATION OF DISEASE: 
 
 
 
Duration of disease No. of patients Percentage 
<5 years 9 20% 
5- 9 years 23 51% 
>10 years 13 29% 
TOTAL 45 100% 
 
      Eighty percent of patients had history of rheumatoid arthritis for 
more than five years. Most number of patients had 5- 9 years of 
disease duration. Mean duration of disease was around 9 years. 
TABLE 5: CLINICAL PARAMETERS: 
 
 
           Out of 45 patients 13(29%) had subcutaneous nodules on 
examination and 15(33%) had some kind of joint deformity.  
           On examination of respiratory system 42% of patients had 
predominant crepitations. 
       RF was positive in 78% of cases and CRP was positive in 85% 
of cases. 
PARAMETER NO. OF 
PATIENTS 
PERCENTAGE 
SUB CUTANEOUS 
NODULES 13 29% 
JOINT DEFORMITY 15 33% 
 
RESPIRATORY SIGNS: 
 
CRACKLES 19 42% 
WHEEZE 10 22% 
NO SIGNS 16 36% 
 
DISEASE ACTIVITY: 
RF  POSITIVE 35 78% 
RF  NEGATIVE 10 22% 
CRP POSITIVE 37 82% 
CRP NEGATIVE 8 18% 
TABLE 6: DISEASE PARAMETERS: 
PARAMETER RANGE MEAN S.D. 
Disease duration 
(yrs) 3- 28 8.93 6.34 
Hb % 8.2- 12 10.04 1.15 
ESR mm/hr 22- 130 55.97 28.77 
DAS 28 score 2.9- 6.51 5.05 0.86 
 
       Mean hemoglobin was around 10 g% and mean ESR was around 56 
mm/hr.  
DAS 28 score ranges between 2.9 to 6.51 with mean value of 5.05 
with standard deviation 0.86 
TABLE 7: DAS 28 SEVERITY: 
 
SEVERITY NO. OF PATIENTS PERCENTAGE 
MILD (≤3.1) 3 7% 
MODERATE (3.2- 5.1) 24 53% 
SEVERE (>5.1) 18 40% 
 
     This table shows that 3 out of 45 (7%) had mild disease and 24 
patients (53%) had moderate disease. 18 people (40%) had severe 
disease activity. 
 
TABLE 8:  ABNORMAL REPORTS: 
Investigation Abnormal Normal Total 
Chest X ray 25 (56%) 20 (44%) 45 
PFT 25 (56%) 20 (44%) 45 
HRCT 32 (71%) 13 (29%) 45 
 
   Out of 45 people 25(56%) had chest X ray and pulmonary function test 
abnormality. 32 patients (71%) had abnormal HRCT findings. 
 TABLE 9: CHEST X-RAY FINDINGS: 
 
FINDING 
NO. OF 
PATIENTS 
PERCENTAGE 
Normal  
20 44.5% 
Increased BVM 
14 31% 
Opacities 
10 22% 
Pleural effusion 
2 4.5% 
 
            Of the total 45 patients, 20(44.5%) had normal chest x ray. 14 
patients (31%) had increased bronchovascular markings and 10 had some 
opacity over the lung parenchyma. Two of them had minimal bilateral 
pleural effusion.  
TABLE 10: CHEST X RAY WITH HRCT FINDINGS: 
 HRCT ABNORMAL 
HRCT 
NORMAL NO. % 
CXR 
ABNORMAL 18 7 25 56% 
CXR NORMAL 14 6 20 44% 
 32 13 45  
P value- 0.84 ( not significant) 
           Chest X ray was abnormal in 18 out of 32 patients (56%) with 
HRCT abnormality and it was normal in 14 patients (44%) with HRCT 
abnormality. 
Seven out of 13(54%) patients with normal HRCT had some chest x ray 
abnormality and Six (46%) patients had normal chest x ray. 
TABLE 11: PFT PARAMETERS: 
 RANGE MEAN S.D. 
FVC ( Litres) 1.22- 2.74 1.83 0.39 
FEV1 (Litres) 0.98- 2.34 1.58 0.35 
FVC % 49- 96 77.4 11.9 
FEV1 % 53- 101 79.2 11.2 
FEV1/FVC % 62- 97 86.4 6.97 
Mean FVC % predicted was 77.4%, the range being 49 to 96%.  
Mean FEV1/FVC was 86.4%, ranges between 62 to 97%.  
 
 
TABLE 12:  PFT PATTERN WITH DURATION OF DISEASE: 
 
 
 
         Seven out of nine (78%) patients with duration of disease < 5 years 
had normal PFT.  Out of 36 patients with disease duration >5 years 
26(64%) had abnormal PFT. There is significant relation between 
duration of disease with PFT abnormality. 
 
TABLE 13: PATTERN OF PFT FINDINGS: 
 
 
PATTERN NO. OF PATIENTS % 
NORMAL 20 45% 
RESTRICTIVE 23 51% 
OBSTRUCTIVE 2 4% 
 
 
        Out of 25 abnormal PFTs 23(92%) had restrictive pattern. Two out 
of 25 (8%) had obstructive pattern of PFT abnormality. 
DURATION NORMAL PFT 
ABNORMAL 
PFT TOTAL
 
P VALUE: 
0.04 
(Significant)
< 5 YEARS 7 2 9 
5- 9 YEARS 10 13 23 
>10 YEARS 3 10 13 
TOTAL 20 25 45 
  
TABLE 14: SEVERITY OF RESTRICTIVE PATTERN: 
 
 
SEVERITY NO. OF PATIENTS % 
MILD 10 43% 
MODERATE 12 52% 
SEVERE 1 5% 
 
     Twelve out of 23(52%) patients had moderate restrictive pattern, 
10(43%) had mild restriction and only one patient had severe restriction 
on PFT.  
 
    Severity of restrictive pattern in pulmonary function test is classified 
according to percentage of predicted FVC89, 90. 
Mild  -  70-79%. 
Moderate -  50- 69% 
Severe  -  <50% 
 
 
 
 
 
 
TABLE 15: HRCT FINDINGS: 
HRCT FINDINGS NO. OF PATIENTS % 
Reticular pattern 23 71.8 
Reticulonodular pattern 8 25 
Ground glass opacities 12 38 
Nodules 4 12.5 
Honey comb pattern 9 28.1 
Bronchiectasis 8 25 
Peribronchial thickening and 
cuffing 10 31.25 
Pleural effusion 8 25 
Pleural thickening 10 31.25 
 
 
 Most of the patients had multiple HRCT findings. 23 out of 32 
patients (72%)  had reticular pattern in HRCT, followed by ground glass 
opacities in 12 patients (38%).  
Pleural thickening and peribronchial thickening and cuffing were 
seen in 31.3% of cases. 
  Honey comb pattern was seen in 28% of cases. 
Bronchiectasis was present in 8 (25%) patients. 
Pleural effusion was present in 25% of cases. 
Pulmonary nodules were seen in only 4(12.5%) cases.  
TABLE 16:  COMPARISON OF HRCT NORMAL AND HRCT 
                      ABNORMAL PATIENTS: 
  
SI 
NO. PARAMETER 
ABNORMAL 
HRCT 
(N= 32) 
NORMAL 
HRCT 
(N= 13) 
TOTAL 
NO. 
PATIENT 
(N= 45) 
P VALUE    
(Chi square 
test) 
1. 
Male 8 2 10 
 
P value- 0.75 
(Not 
significant) 
 Female 24 11 35 
2. Duration of 
disease 
 < 5 years 
4 5 9 
 
P value-0.042
(Significant) 
 >5 years 28 8 36 
3. Sub cut. nodules 
Present 12 1 13 
 
P value-0.042
(Significant) 
Absent 20 12 23 
4. RF positive 28 7 35  P value-0.03 
(Significant) RF negative 4 6 10 
5. CRP positive 27 10 37 P value- 0.08 
(Not 
significant) CRP negative 5 3 8 
6. 
PFT abnormal 21 4 25 
 
 
P value-0.043
(Significant) 
PFT normal 11 9 20 
 
           There is no significant difference between males and females 
in the occurrence of HRCT abnormalities (p value- >0.05). But out 
of 10 male patients 8 (80%) had HRCT abnormalities in contrast to 
females, in which 22 out of 35 (69%) had the same. 
        There is statistically significant relation between the duration of 
disease. Out of nine patients who had disease duration <5 years, only 
4(44%) had HRCT abnormalities. 28 patients out of 36 (78%), who 
had disease duration >5 years, had HRCT abnormalities. 
        Those who have subcutaneous nodules have high chance 
occurrence of HRCT abnormality. Out of 13 patients with 
subcutaneous nodules 12 (92%) had some HRCT abnormalities. 
        There is significant relation between Rheumatoid factor 
positivity and HRCT abnormality. 28 out of 32 (88%) patients with 
HRCT findings had RF positivity. Only 7 out of 13 (54%) patients 
with normal HRCT had RF positivity. 
       There is no significant relation between CRP positivity and 
HRCT findings.  84% (27/32) of HRCT abnormal patients had CRP 
positivity and 77% (10/13) of patients with normal HRCT also had 
CRP positivity. 
        
    
          There was significant association between HRCT and PFT 
findings. 21 out of 32 patients (66%) with HRCT findings have PFT 
abnormalities. Nine out of 13 (69%) patients with normal HRCT 
have normal PFT. 34% of HRCT abnormal patients show a normal 
PFT pattern and 31% of HRCT normal patients show an abnormal 
PFT. 
          Specificity and sensitivity calculated in comparison with 
HRCT finding were 69% and 66% respectively. Positive predictive 
value of PFT was 84% and negative predictive value of PFT was 
only 45%. 
 
  
                                    DISCUSSION 
      Rheumatoid arthritis (RA) is a chronic multi-system disease of 
unknown cause. It is a systemic inflammatory disease and affects 1-2% of 
the general 
population. A major portion of morbidity and mortality are due to RA are 
due to its extra-articular manifestations.  A variety of pulmonary 
manifestations are associated with RA and lung disease is the second 
most common cause of death (18%) after infection (27%) in patients with 
RA91.  
     In our study, we selected 45 patients from Rheumatology clinic, Govt. 
Rajaji Hospital, Madurai, who are already diagnosed to have Rheumatoid 
arthritis as per American Rheumatism Association guidelines. We 
selected those patients who have either respiratory symptoms or signs. 
        The sex distribution in this study, predominantly affects females in 
the ratio of 3.5:1. According to Harrison 17th edition, API text book of 
medicine, the females are affected 3 times more than males. In this study 
males are 22% and females are 78%. Doran MF, Ponal et al study, males 
are 26.9% and females are 73.1%92. In a study conducted by Raniga S, 
Sharma P et al in 2006, the female to male ratio was 3:193. There were 
23.3% males and 76.7% females. 
        The mean age in our study is 47.7 years. Most number of cases in 
between 50- 59 years (35.6%). In a study conducted by Raniga et al, 
average age of male patients was 48.4 years and for females 45.8 years93. 
The average age of patients in our study was comparable to that of other 
studies. The mean age of onset of lung disease was in the fifth or sixth 
decade. 
     In this study, average duration of rheumatoid arthritis is 8.9 ± 6.3 
years. 
Most number of patients is in between 5- 9 years of age (51%). In a study 
by Tanaka et al on rheumatoid arthritis related lung diseases average 
duration of disease was 7.6 ± 9.2 years94. In a study conducted by 
Stephen C Morrison et al, average duration of disease was 12.4 years95. In 
a study by R Prasad et al99 the mean age of study group were 52.6 years 
(Range 18-66) and the mean duration of rheumatoid arthritis was 11.9 
years. 
     In this study, predominant respiratory symptom is dyspnoea, which 
was present in 30 patients out of 45 (67%), followed by dry cough in 40% 
(18 out of 45) patients. In a study by G S Gaude et al also the most 
common symptom was dyspnoea in 57% of patients (68 out of 119), 
followed by dry cough (59 out of 119)96. 
        In our study, 12 out of 13 patients (92%) with rheumatoid nodule are 
RF positive. Rheumatoid nodules are more common in males than in 
females and are closely associated with RF seropositivity98. But in our 
study, only four out of 13 patients (31%) with subcutaneous nodules are 
males. 
       Patients with rheumatoid nodules were more likely to have lung 
involvement. In our study population, 12 patients with rheumatoid nodule 
had HRCT findings and only one patient with nodule had normal HRCT. 
In S Raniga et al study, three patients with rheumatoid nodules had 
HRCT findings consistent with ILD and no patient without lung 
involvement had rheumatoid nodule93.  
       In our study respiratory signs in the form of crackles or wheeze were 
present in 64% of patients, in contrast to Raniga et al study where, that 
was present in only 10% of patients. This may be due to the fact that we 
included only symptomatic cases in our study, but Raniga et al study 
included all rheumatoid patients irrespective of respiratory symptoms.   
         In our study RF is positive in 78% (35 out of 45) of cases and there 
is high correlation between RF positivity and pulmonary manifestations. 
In Raniga et al study, RF was positive in 83.3% of cases93. 
       Müller- Leisse C et al, in his study states that RA with HRCT 
findings were associated with higher level of RF and there was no 
relationship between pulmonary changes and either the duration of the 
disease, antinuclear antibodies (ANA) or C-reactive protein97. In our 
study 82% of patients are CRP positive. But there is no significant 
relation between HRCT findings and CRP positivity. 
      In our study average DAS 28 score is 5.05±0.86, most of the patients 
are in moderate severity (score between 3.2- 5.1). 24 out of 45 patients 
(53%) are of moderate disease activity. 40% of patients have severe 
disease activity according to DAS 28. Toshihisomatsui et al100 in their 
study reported 11.6% patients had mild disease, 51.4% had moderate 
DAS score and 45.5 % of patients had severe disease activity. In our 
study there is no significant correlation between DAS28 severity and 
HRCT findings. 
        In our study, 25 out of 45 patients (56%) show abnormal chest x ray. 
18 patients out of 32 (56%) with HRCT findings show abnormal x ray 
and 14 out of 32 patients (44%) with HRCT findings have normal chest x 
ray. Seven out of 13 patients (54%) with normal HRCT have x ray 
abnormalities. Sensitivity and specificity of chest x ray in detecting 
pulmonary manifestations, with respect to HRCT are 56% and 46% 
respectively. Most of the patients with abnormal x ray shows increased 
bronchovascular markings (14 out of 25), which is highly nonspecific. 10 
patients (40%) show reticular and reticulonodular opacities suggestive of 
ILD. Two patients have minimal pleural effusion in the x ray. 
          In this study, 25 out of 45 (56%) patients show abnormal PFT. PFT 
findings has got positive correlation with the duration of disease in this 
study.23 out of 36 (64%) patients with duration >5 years show PFT 
changes. 22% (two out of nine) of patients with duration <5 yrs show 
PFT changes. 
          21 out of 32 (66%) patients with abnormal HRCT have abnormal 
PFT. 11 out of 32 patients (34%) with abnormal HRCT have normal PFT. 
Out of normal HRCT patients 69% of patients have normal PFT. 
Sensitivity and specificity of PFT are 66% and 69% respectively in our 
study. Out of 25 patients with abnormal PFT, 23 (92%) have restrictive 
pattern, 2 patients show obstructive pattern. Of the restrictive patients, 10 
(44%) show mild restriction, 8 (38%) have moderate restriction and 4 
patients show severe restriction. 2 cases of obstructive pattern are 
associated with bronchiectasis in HRCT.  
      Mean FVC is 1.83L ±0.39. Average percentage predicted FVC is 77.4 
± 12%. Mean FEV1/FVC is 86.4 ±6.97%.  
           In the study conducted by Raniga et al, abnormalities detectable on 
chest radiograph were 13.33%. Chest x-ray showed changes consistent 
with ILD in 4/30 (13.3%) including bilateral reticular infiltrates in three 
and honeycombing in one and x-ray chest was normal in 7/11 (63.6%) 
patients with HRCT positive ILD. Chest radiograph is the least sensitive 
with only four out of thirty patients shows findings consistent with 
interstitial disease. In our study, the ability of PFTs to pick up an 
abnormality was better than the chest radiographs which were 66% and 
56% respectively. 
         In a study conducted by McDonagh et al103, spirometric 
abnormalities were noted in 8/30 (26.6%) and radiological abnormality 
in13%. In the same study, HRCT findings consistent with ILD were seen 
in eleven out of thirty patients (36%), compared to the spirometric 
findings in 8/30 (26.6%). The results of HRCT have not been shown to 
correlate with pulmonary function tests. But in our study there is 
significant correlation between HRCT and PFT results.  
      In a study conducted by R Prasad et al, spirometry showed restrictive 
pattern in 52.9 % cases (Mean FEV1/FVC 86 % and Mean FVC 1.16 
Litre) and obstructive pattern noted in 11.8 % while 6 (35.3 %) patients 
did not cooperate99. 
       In a study conducted by Cervantes-Perez et al, no correlation was 
found between the disease duration, the number of patients and the 
severity of restrictive PFT abnormality101. But in our study there is a 
positive correlation between duration and PFT changes. This may be due 
to very less number of patients (9 out of 45) who have disease duration 
<5 years and mean duration of disease is 9 years. We haven’t screened 
asymptomatic subjects, who are in the early stages of the disease. In our 
study we have positive correlation between HRCT findings and duration 
of disease also. 
       In G S Gaude et al study, pulmonary functions were abnormal in 
almost 89% of the patients with RA and the most common defect in these 
patients was restrictive defect (79%). HRCT shows evidence of 
interstitial lung disease in 11 out of 30 patients and so the most sensitive 
of all parameters96  
      The HRCT study by Fewins et al of patients with RA revealed a high 
prevalence of ILD (44%) with maximum patients having mild restriction 
and lesser patients having moderate and severe restriction102. 
        In our study 32 patients out of 45(71%) have abnormal HRCT. Out 
of 32, there are 8 males and 24 females. There is no significant difference 
between male and female in occurrence of HRCT abnormality. But, out 
of 10 males, 8 (80%) have HRCT findings and out of 35 females, 24 
(69%) have the same. 
The pleuropulmonary manifestations of RA are seen more 
commonly in men than women105. 
       The spectrum of RA-associated lung is extremely broad. A 
multiplicity of CT patterns is commonly seen in patients with rheumatoid 
arthritis. The ILD is the most common manifestation of RA106. Finding 
consistent with Interstitial Lung disease (ILD) was defined as the 
presence of GGO, IPF (reticular pattern, honeycombing), traction 
bronchiectasis, or interlobular septal thickening.  High resolution 
computed tomography is a more sensitive method of detecting ILD and 
pleural effusion.  
       The HRCT study by Fewins et al102 of patients with RA revealed a 
high prevalence of ILD (44%). In Raniga et al study, prevalence of ILD is 
36%93. 
     In our study, of the 32 cases with HRCT findings, 72% have reticular 
pattern (23/32 patients), followed by ground glass pattern which comes 
around 38% (12 cases). Honeycombing is seen in 9 patients (28%). 
Tractional bronchiectasis is present in 25% of cases.28 out of 32 HRCT 
findings are consistent with the presence of ILD (88%).  
       Pleural involvement in the form of pleural effusion (25%) and pleural 
thickening (31%) are observed. Isolated pleural involvement is rare and is 
present in 2 cases (6%). Pulmonary nodules are seen in 4 cases (13%). 
Almost all cases with ground glass opacities occur along with reticular 
pattern or honeycomb pattern. 
       In BIEDERER J et al study104, in 49 of 53 patients, HRCT was 
suggestive of ILD associated with RA. Reticular lesions were found in 40 
of 53 patients, in 15 of 40 presenting as mixed pattern with ground-glass 
opacities (GGO). Pure reticular patterns predominated in patients with 
long duration of ILD. Pure GGO were not observed. 
      In the Gaude et al study96, Reticular, nodular and the combined 
pattern were observed in the majority of the cases (58.9%). Interstitial 
pattern consistent with ILD was observed in 44.5% of the patients. The 
common abnormality observed was reticulonodular lesions on HRCT of 
the thorax.  Pleural effusions were observed in 8% of the cases and 
bronchiectasis was observed in 5% of the patients with RA. 
Bronchiectasis has been reported in as many as 30% of patients with RA 
undergoing HRCT. 
    In Müller- Leisse C et al study97, 58 patients (70%) had pathological 
CT scans showing the following abnormalities: interlobular thickening 
(44.5%), intralobular thickening (34%), nonseptal linear attenuation 
(35%), nodular or linear pleural thickening (32.5%), ground-glass pattern 
(19%), centrilobular nodules (13%), honeycombing (13%) and 
bronchiectasis (9%). 
 
 
             In Tanaka et al study94, ground glass opacity (57 [90%] patients) 
and reticulation (62 [98%] patients) were the most common CT features. 
Four major CT patterns were identified: usual interstitial pneumonia 
(n=26), nonspecific interstitial pneumonia (n=19), bronchiolitis (n= 11), 
and organizing pneumonia (n=5). Usual interstitial pneumonia and 
nonspecific interstitial pneumonia CT patterns overlapped; GGO was 
more extensive in patients with nonspecific interstitial pneumonia CT 
pattern.  
     
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
1. Sex ratio of female to male in this study is 3.5:1 
2. Most of the patients are distributed between 50- 59 years. 
3. Dyspnoea on exertion is the most common respiratory symptom. 
4. 80% of patients have history of Rheumatoid arthritis for more than 5 
years. Average duration of disease is 9 years. 
5. Rheumatoid factor is positive among 78% of cases. There is high 
correlation between RF positivity and lung involvement. 
6. 92% of patients with subcutaneous nodule are RF positive. Patients with 
subcutaneous nodules are more likely to have lung manifestations. 
7. PFT and HRCT findings have positive correlation. Mild restrictive 
pattern is the most common abnormal PFT pattern. 
8. PFT and HRCT abnormalities have got positive correlation with duration 
of disease.  
9.  HRCT is the most sensitive modality to detect lung involvement in 
rheumatoid arthritis. HRCT can show evidence of ILD even when PFT 
parameters and chest radiograph are normal.  
10. ILD is the most common pulmonary manifestation (88%) in Rheumatoid 
arthritis in the form of reticular and ground glass pattern in HRCT. 
                                    SUMMARY 
        The study “Pulmonary manifestations of Rheumatoid arthritis” is a 
descriptive study conducted on patients attending Rheumatology outpatient 
department, Govt. Rajaji Hospital, Madurai. Forty five patients of Rheumatoid 
arthritis with either respiratory symptoms or signs are included in the study. 
Selected patients underwent clinical, laboratory investigations, pulmonary 
function test, chest x ray and HRCT to detect pulmonary involvement. 
       The information collected regarding all cases were recorded in a master 
chart and data analysis done with the help of Epidemiological Information 
Package (EPI 2008). 
     Analyzing the data shows sex ratio among study population of 3.5:1 with 
female predominance. 50- 59 years of age is most commonly involved. 80% of 
patients are with duration of disease more than 5 years. Most common 
respiratory symptom is dyspnoea. 78% of patients are rheumatoid factor 
positive. There is high correlation between lung involvement and RF positivity. 
92% of patients with subcutaneous nodules are RF positive. Patients with 
nodules are more likely to develop lung manifestations. Restrictive pattern is 
the commonest PFT finding. PFT and HRCT have got positive correlation. 
HRCT is the most sensitive modality to detect lung involvement. ILD is the 
most common pulmonary manifestation of Rheumatoid arthritis in the form of 
reticular pattern in HRCT. 
GLOSSARY 
RA                  -         Rheumatoid arthritis 
RF                   -         Rheumatoid factor 
CRP                -         C reactive protein  
ESR                -         Erythrocyte sedimentation rate  
Hb                   -         Hemoglobin 
DAS                -         Disease activity score 
Anti CCP        -         Anti cyclic citrullinated protein 
DMARD         -         Disease modifying anti rheumatic drugs 
PFT                 -         Pulmonary function test 
HRCT             -         High resolution computed tomography 
FVC                -         Forced vital capacity 
FEV1              -         Forced expiratory volume in first one second 
FEF                -          Forced expiratory flow 
ILD                -          Interstitial lung disease 
IPF                 -          Idiopathic pulmonary fibrosis 
GGO              -          Ground glass opacity 
UIP                -          Usual interstitial pneumonia 
NSIP              -          Nonspecific interstitial pneumonia 
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  PROFORMA 
NAME: 
                                                         AGE:                SEX:                         
OP NO: 
ADDRESS:  
                                  
PHONE NO: 
 
HISTORY: 
Arthritis:                                                                  EYE: 
Nodules:                                                        Scleritis/episcleritis: 
Raynaud’s phenomenon:                                         Dry eyes: 
Sicca symptoms:                                                         
Cough/expectoration/dyspnoea/chest pain:                                     
 
                                                                                 No. of tender joints: 
Fever:                                                                       No. of swollen joints: 
Muscle weakness- proximal/distal/neck/trunk 
                                                                                 DAS 28 score: 
PAST HISTORY:                                                                            
                                                                                 Deformity: 
DM/HT/TB/ATT/CAD 
 
PERSONAL HISTORY: 
 
Smoking/Alcohol/ exposure to STD 
 
FAMILY HISTORY: 
 
DM/HT/CAD/Rheumatic diseases 
 
Systemic examination: 
 
RS:                                                                                      CVS: 
 
ABDOMEN:                                                                       CNS: 
 
INVESTIGATIONS: 
HEMATOLOGY:   
                                                                      RFT:                              
B.Sugar:                                                                                         
Hb:                                                                B.UREA:                       
S.cholesterol:                                                               
TC:                                                                S.Cr: 
DC:                                                               S.Electrolytes: 
ESR: 
LFT: 
RF: 
CRP: 
 
X-RAY Chest: 
 
 
 
PFT: 
 PATIENT 
VALUE
PREDICTED 
VALUE
PERCENTAGE 
FVC    
FEV1    
FEV1/FVC    
                                           
 
 IMPRESSION: 
 
HRCT CHEST: 
 
 
 
 
 HRCT showing Peribronchial thickening with  
ground glass opacity and tractional bronchiectasis 
 
 
 
HRCT showing Reticular pattern of opacities 
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1 VATSALA 52 F 3 N N Y N N Y Y N 8.2 40 + + 4.77 Y N Y N Y N Y N N N N N Y 1.24 1.15 59 62 93 RES
2 RAJAMANI 60 F 6 N N Y Y N N Y N 11 55 + + 6.51 N N N N Y N Y N Y N N N N 1.66 1.36 69 68 82 RES
3 SIVANACHIAR 55 F 4 Y N Y N N N Y N 9.6 68 + + 5.78 Y Y N N Y N N N N N Y Y N 1.7 1.46 76 78 86 RES
4 PONNUSAMY 40 M 10 Y N N N Y Y N N 11 65 ‐ + 3.98 Y Y N N Y N Y N Y N N N N 1.52 1.32 57 65 87 RES
5 RATINAM 59 F 5 Y N Y N N Y N N 10 55 + ‐ 4.23 Y N Y N Y N N N N N Y N Y 2.74 2.34 92 89 85 NOR
6 BALAKRISHNAN 55 M 7 Y N N N Y N Y N 10 115 + + 6.33 N N N N N Y N N N N N N N 1.31 1.12 67 69 86 RES
7 JANAKI 38 F 4 N N Y N N N N N 9.8 50 + + 5.33 N N N N N N Y N N N Y N Y 1.86 1.64 95 101 88 NOR
8 NAZIMA BEGAM 35 F 11 Y N N N N N N Y 11 52 + + 5.3 Y Y N N Y N Y N Y N N N N 1.42 1.23 72 76 86 RES
9 RAJAMMAL 35 F 15 N N Y N Y N N N 8.2 135 + + 5.86 N N N N Y N N Y N N N Y N 1.86 1.62 83 91 87 NOR
10 SARASWATHY 32 F 10 N N N N N N Y N 8.8 90 + + 4.53 N N N N Y N Y N N Y N N N 1.33 1.24 59 70 93 RES
11 VIJAYALAKSHMI 57 F 5 Y Y Y N N Y Y N 12 32 + + 4.75 Y N Y N Y N Y Y N Y N N N 1.82 1.48 82 76 81 NOR
12 KADAMBAN 62 M 26 N N Y N Y N N Y 12 36 + ‐ 5.12 N N N N Y Y N N N N Y N N 1.54 1.51 64 76 98 RES
13 RAJESWARI 48 F 22 Y N N N Y Y N N 11 22 + + 4.92 N N N N N N N N Y Y N N Y 2.45 2.24 85 97 91 NOR
14 POONGODI 44 F 7 N N N N N N Y N 8.6 35 + + 5.38 N N N N Y N Y N Y N N N N 1.96 1.84 68 79 94 RES
15 R.LATHA 39 F 6 N N Y Y N Y Y N 13 50 + + 4.93 Y Y N N Y Y N N N N N N N 2.12 1.68 84 86 80 NOR
16 RAJA 46 M 6 Y N N N N N N Y 12 44 + + 5.12 Y Y N N Y Y N N N N N Y N 1.49 1.34 66 71 90 RES
17 ESWARI 47 F 15 N N Y N Y Y Y N 8.8 60 + + 5.55 Y N Y N N N N N Y N N Y N 1.98 1.68 88 86 85 NOR
18 SELVARAJ 52 M 8 N N Y N N N N Y 11 38 ‐ + 4.12 N N N N N N N N Y N Y N N 2.45 2.12 86 83 87 NOR
19 RAJAMMAL 50 F 16 N N Y N Y Y Y N 9.8 32 + + 5.68 Y N Y N Y N Y N N N N N Y 1.54 1.34 65 68 87 RES
20 NOORJAHAN 36 F 7 Y N N N N N N Y 9.8 40 + + 5.1 Y N N Y N N N N N N N Y Y 1.68 1.48 77 79 88 RES
21 KANNAMMAL 56 F 6 Y N Y y Y N N N 10 54 + ‐ 5.97 Y N Y N Y Y N N N N Y N N 1.59 1.32 80 74 83 NOR
22 SUNDARAM 43 M 11 N N Y N N Y N N 9.6 60 + + 6.34 N N N N N N N N N Y Y Y N 1.72 1.56 74 83 91 RES
23 PERIMBAM 53 F 5 N N N N Y N N N 11 130 + + 6.11 Y Y N N Y N N N Y N N N Y 0.98 0.87 49 53 89 RES
24 AROGYAM 40 M 4 N N Y N N N N Y 9.6 25 + + 4.79 Y Y N N Y N N N N Y N N N 2.43 2.12 96 96 87 NOR
25 PARAMESWARI 40 F 6 N N N N Y N Y N 9.2 26 + + 4.98 Y N Y N N N Y Y N Y N N Y 1.74 1.12 91 63 64 OBS
26 BALARAMAN 51 M 25 Y N Y y N Y Y N 12 30 + ‐ 4.21 N N N N Y N Y N Y N Y N N 1.98 1.86 77 79 94 RES
27 NEETHI THAI 60 F 28 Y N Y N N N Y N 10 75 + + 6.36 Y Y N N Y N N Y N Y N N N 1.58 0.98 78 55 62 OBS
28 ATHIJAYALAKSM 54 F 7 N N Y N Y N Y N 9 40 + + 3.1 N N N N Y Y N N N N Y N N 1.63 1.42 57 62 88 RES
29 RAMUTHAI 62 F 7 N N N N N N Y N 8.6 60 ‐ + 5.66 Y Y N Y Y Y N N N N N Y N 1.82 1.76 69 81 97 RES
30 ANUSIYA 45 F 6 Y Y Y N N Y Y N 10 120 ‐ + 4.65 N N N N Y N N N N Y N N N 2.21 2.02 76 80 91 RES
31 SHANTHI 30 F 7 N N Y N Y Y Y N 9 48 + + 4.71 Y N Y N Y Y Y N N N Y N Y 1.56 1.42 70 76 91 RES
32 FATHIMA 57 F 7 N N Y N N N N N 9.6 42 + ‐ 4.1 N N N N N N N N N N N Y Y 2.34 1.87 82 84 80 NOR
33 ANGAMMAL 65 F 8 N N y N N Y N Y 10 40 ‐ + 4.8 Y N Y N N N N N N N N N N 1.98 1.56 85 84 79 NOR
34 SELVI 47 F 3 N N Y N N N N N 9.8 45 + ‐ 5.13 Y Y N N N N N N N N N N N 1.98 1.67 85 80 84 NOR
35 MURUGAN 39 M 4 Y N N N N N N Y 12 38 ‐ + 4.8 N N N N N N N N N N N N N 1.86 1.68 93 103 90 NOR
36 VIJAYA  43 F 12 N N Y N N N N N 8.6 70 + + 6.12 N N N N N N N N N N N N N 1.54 1.41 72 80 92 RES
37 LALITHA 55 F 7 Y Y Y N N N N Y 9.6 68 + ‐ 4.8 Y Y N N N N N N N N N N N 2.42 2.12 90 91 87 NOR
38 GURULAKSHMI 38 F 5 N N Y N N N Y N 8.8 40 + + 3.1 N N N N N N N N N N N N N 2.42 2.12 93 91 88 NOR
39 JAYA 50 F 6 N N Y N N Y N N 8.6 130 ‐ + 4.78 Y Y N N N N N N N N N N N 2.12 1.64 86 83 77 NOR
40 MANJULA 31 F 3 Y N N y N N N N 8.8 30 ‐ ‐ 5.12 Y Y N N N N N N N N N N N 1.97 1.68 88 82 85 NOR
41 PANDIAN 46 M 7 Y N Y N Y N N Y 12 54 + + 5.5 N N N N N N N N N N N N N 1.84 1.68 71 82 91 RES
42 THENMOZHI 49 F 4 Y N N N N N Y N 9.8 50 ‐ + 2.9 Y N Y N N N N N N N N N N 2.2 1.76 89 89 80 NOR
43 KUMUTHA 52 F 8 N N Y N N N N N 10 44 + + 4.2 Y Y N N N N N N N N N N N 1.22 1.12 74 78 92 RES
44 SUPPU 43 F 3 N N Y y N N N N 11 50 + + 5.67 N N N N N N N N N N N N N 2.21 1.78 96 92 81 NOR
45 RAJAMANI 56 F 20 N N Y N N Y N N 9.8 36 ‐ + 6.24 N N N N N N N N N N N N N 1.34 1.21 68 75 90 RES
KEY TO MASTER CHART
M  ‐   MALE                     F   ‐   FEMALE               +   ‐  POSITIVE                            ‐     NEGATIVE
Y   ‐    PRESENT              N  ‐   ABSENT               RES ‐ RESTRICTIVE           OBS ‐ OBSTRUCTIVE
NOR  ‐  NORMAL
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